UBS lifts Teva stock price target to $30, maintains Buy rating
UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...
Keefe analysts lift Nicolet Bankshares target to $115
Keefe, Bruyette & Woods adjusted their outlook on Nicolet Bankshares (NASDAQ:NCBS) (NYSE: NIC (NASDAQ:EGOV)), increasing the price target to $115 from the previous $110, while retaining a Market ...